These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 12003983

  • 1. BMS284756 (formerly T-3811, a des-fluoroquinolone) potency and spectrum tested against over 10,000 bacterial bloodstream infection isolates from the SENTRY antimicrobial surveillance programme (2000).
    Gordon KA, Pfaller MA, Jones RN, SENTRY Participants Group.
    J Antimicrob Chemother; 2002 May; 49(5):851-5. PubMed ID: 12003983
    [Abstract] [Full Text] [Related]

  • 2. Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000).
    Kirby JT, Mutnick AH, Jones RN, Biedenbach DJ, Pfaller MA.
    Diagn Microbiol Infect Dis; 2002 Aug; 43(4):303-9. PubMed ID: 12151191
    [Abstract] [Full Text] [Related]

  • 3. Comparative antimicrobial spectrum and activity of the desfluoroquinolone BMS284756 (T-3811) tested against non-fermentative Gram-negative bacilli.
    Howard W, Biedenbach DJ, Jones RN.
    Clin Microbiol Infect; 2002 Jun; 8(6):340-4. PubMed ID: 12084101
    [Abstract] [Full Text] [Related]

  • 4. Comparative antimicrobial spectrum and activity of BMS284756 (T-3811; a desfluoroquinolone) tested against an international collection of staphylococci and enterococci, including in vitro test development and intermethod comparisons.
    Pfaller MA, Beach ML, Gordon KA, Jones RN.
    J Chemother; 2002 Feb; 14(1):13-8. PubMed ID: 11892893
    [Abstract] [Full Text] [Related]

  • 5. Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp.
    Rhomberg PR, Biedenbach DJ, Jones RN.
    Diagn Microbiol Infect Dis; 2001 Feb; 40(1-2):45-9. PubMed ID: 11448563
    [Abstract] [Full Text] [Related]

  • 6. Comparative antimicrobial spectrum and activity of BMS284756 (T-3811, a desfluoroquinolone) tested against 656 Enterobacteriaceae, including preliminary in vitro susceptibility test comparisons and development.
    Fix AM, Pfaller MA, Biedenbach DJ, Beach ML, Jones RN.
    Int J Antimicrob Agents; 2001 Aug; 18(2):141-5. PubMed ID: 11516937
    [Abstract] [Full Text] [Related]

  • 7. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).
    Fritsche TR, Sader HS, Jones RN.
    Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139
    [Abstract] [Full Text] [Related]

  • 8. Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
    Biedenbach DJ, Jones RN, Pfaller MA, Sentry Participants Group (Americas and Europe).
    Diagn Microbiol Infect Dis; 2001 Apr; 39(4):245-50. PubMed ID: 11404068
    [Abstract] [Full Text] [Related]

  • 9. Activity and spectrum of BMS 284756, a new des-F (6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci.
    Jones RN, Pfaller MA, Stilwell M, SENTRY Antimicrobial Surveillance Program Participants Group.
    Diagn Microbiol Infect Dis; 2001 Feb; 39(2):133-5. PubMed ID: 11248528
    [Abstract] [Full Text] [Related]

  • 10. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA.
    McCloskey L, Moore T, Niconovich N, Donald B, Broskey J, Jakielaszek C, Rittenhouse S, Coleman K.
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():13-21. PubMed ID: 10824027
    [Abstract] [Full Text] [Related]

  • 11. In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.
    Otani T, Tanaka M, Ito E, Kurosaka Y, Murakami Y, Onodera K, Akasaka T, Sato K.
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3750-9. PubMed ID: 14638477
    [Abstract] [Full Text] [Related]

  • 12. Comparative in-vitro activities of trovafloxacin, ciproflaxacin, ofloxacin, and broad-spectrum beta-lactams against aerobe blood culture isolates.
    Seifert H.
    Zentralbl Bakteriol; 1998 Dec; 288(4):509-18. PubMed ID: 9987189
    [Abstract] [Full Text] [Related]

  • 13. The in vitro activity of BMS-284756, a new des-fluorinated quinolone.
    Weller TM, Andrews JM, Jevons G, Wise R.
    J Antimicrob Chemother; 2002 Jan; 49(1):177-84. PubMed ID: 11751785
    [Abstract] [Full Text] [Related]

  • 14. In-vitro activity of PD 117 596, a new quinolone, against bacterial isolates from cancer patients.
    Rolston KV, LeBlanc B, Ho DH, Bodey GP.
    J Antimicrob Chemother; 1990 Jul; 26(1):39-44. PubMed ID: 2211445
    [Abstract] [Full Text] [Related]

  • 15. Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.
    Harnett SJ, Fraise AP, Andrews JM, Jevons G, Brenwald NP, Wise R.
    J Antimicrob Chemother; 2004 May; 53(5):783-92. PubMed ID: 15056651
    [Abstract] [Full Text] [Related]

  • 16. Comparative activities of six different fluoroquinolones against 9,682 clinical bacterial isolates from 20 European university hospitals participating in the European SENTRY surveillance programme. The SENTRY participants group.
    Schmitz FJ, Verhoef J, Fluit AC.
    Int J Antimicrob Agents; 1999 Aug; 12(4):311-7. PubMed ID: 10493607
    [Abstract] [Full Text] [Related]

  • 17. Assessment of BMS284756 MIC and 5-microg disk diffusion quality control studies tested against seven American type culture collection strains.
    Biedenbach DJ, Jones RN, Quality Control Working Group.
    Diagn Microbiol Infect Dis; 2001 Dec; 41(4):225-8. PubMed ID: 11777665
    [Abstract] [Full Text] [Related]

  • 18. Antimicrobial activity of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients.
    Rolston KV, Frisbee-Hume S, LeBlanc BM, Streeter H, Ho DH.
    Diagn Microbiol Infect Dis; 2002 Oct; 44(2):187-94. PubMed ID: 12458127
    [Abstract] [Full Text] [Related]

  • 19. In-vitro activity of PD 117558, a new quinolone against bacterial isolates from cancer patients.
    Rolston KV, LeBlanc B, Gooch G, Ho DH, Bodey GP.
    J Antimicrob Chemother; 1989 Mar; 23(3):363-71. PubMed ID: 2732120
    [Abstract] [Full Text] [Related]

  • 20. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin.
    Fung-Tomc J, Minassian B, Kolek B, Washo T, Huczko E, Bonner D.
    J Antimicrob Chemother; 2000 Apr; 45(4):437-46. PubMed ID: 10747819
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.